GenSensor a DeepTech start-up and Servier, a global pharmaceutical group, today announced a new initiative in the form of expert mentoring to accelerate the industrialization of an innovative Process Analytical System to better produce biomedicine.
Following the 7th France Bioproduction Congress organized by PolePharma (top industrial cooperation for drugs in Europe) and MediCen (health competitiveness cluster, Île-de-France, France), Servier has decided to follow GenSensor in their development, sharing bioproduction pitfalls and constraints.
“This mentoring initiated after the French Bioproduction Congress 2022 furthers Servier’s goal and effort to support the great challenge of bioproduction: improving yield, quality and in process documentation” comments Hélène Négre, Scientific Director Biotechnology & Bioproduction.
Building an exchange/a sharing place between a start-up and a pharmaceutical group – that produces its drugs – is a way to accelerate the development of the product while ensuring its compatibility and deployment in an industrial setting. It is an opportunity for GenSensor to co-construct an innovative tool fully aligned with the needs of innovative drug producers.
Charles Hébert, CEO at GenSensor comments: “Our vocation is to improve the way a biomedicine is produced. Joining the experience of a large laboratory and an expert team accelerates our development and secures it. As a pioneer in the field, it is also an opportunity to promote the use of genomics as the PAT of the future.”
“Growing fast and strong is a real challenge for young companies, and Servier is engaged to support entrepreneurs in this journey. Expert mentoring is an interesting way for Servier to share its industrial experience with GenSensor, and we are very happy to build these dynamics that will ultimately benefit to patients” concludes Olivier Nosjean, Head of Global Open Innovation and Scientific Affairs at Servier.
About GenSensor
GenSensor is a DeepTech start-up that develops innovative in-line Process Analytical Technology (PAT). Its technology is based on real time cell sequencing during production. GenSensor aims to improve the production of biological drugs. GenSensor is supported by Atlanpole and financed by the BPI. GenSensor is part of France’s 2030 national health strategy to accelerate biotherapies and bioproduction of innovative therapies by improving production yields and capacity, reducing production costs.
About Servier
www.servier.com